Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance ...

Tirzepatide use vs placebo was associated with slower decline in eGFR among patients with prediabetes and obesity or overweight.

In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is ...

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with overweight or obesity compared to use of tirzepatide treatment alone ...

HealthDay News — In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is associated with superior weight loss outcomes, according to ...

The researchers reported that tirzepatide (0% to 40.6%) and semaglutide 2.4 mg (0% to 32.2%) increased significantly among adults without diabetes with any or incident use of WLMs, though ...

Tirzepatide may confer larger increases in testosterone levels among men with metabolic hypogonadism than testosterone ...

Most individuals (95.6%) initiated a tirzepatide dose of below 5 mg. Among the 448 patients who received a 5th prescription refill, 91.1% were receiving tirzepatide doses of no more than 10 mg.

Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, among women than men.